ANXA2 and bladder transitional cell carcinoma: TRIM65 enhances the invasiveness of bladder urothelial carcinoma (BUC) cells by inducing epithelial–mesenchymal transition (EMT) and promoting the ubiquitination and degradation of Annexin A2 (ANXA2) [25].